Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy

Background Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial subjects to ensure trial subject safety and data accuracy. This study dete...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMC cancer Ročník 21; číslo 1; s. 324 - 6
Hlavní autori:	Marcath, Lauren A., Finley, Colin M., Wong, Siu Fun, Hertz, Daniel L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 26.03.2021 BioMed Central Ltd Springer Nature B.V BMC
Predmet:	Acids Administration, Oral Analgesics Antacids Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Cancer Research Cancer therapies Chemotherapy Clinical trials Complications and side effects Contraindications Drug interactions Drug Interactions - physiology Enrollments Epidemiology Female Health Promotion and Disease Prevention Humans Inhibitor drugs Male Medicine/Public Health Neoplasms - drug therapy Oncology Oncology clinical trial drug interaction Oral cancer Oral medication Patient safety Pharmaceutical research prevention and public health Research Article Standard deviation Statistical analysis Surgical Oncology Testing Toxicity United States Oncology clinical trial drug interaction
ISSN:	1471-2407, 1471-2407
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!